The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: A meta-analysis

Gut

Volumn 61, Issue 7, 2012, Pages 970-976

  Desai, Tusar K ^a   Krishnan, Kumar ^b   Samala, Niharika ^a   Singh, Jashanpreet ^a   Cluley, John ^b   Perla, Subaiah ^c   Howden, Colin W ^b  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c OAKLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGE DISTRIBUTION; ARTICLE; BARRETT ESOPHAGUS; CANCER INCIDENCE; CANCER MORTALITY; ESOPHAGEAL ADENOCARCINOMA; HUMAN; NON DYSPLASTIC BARRETT ESOPHAGUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SYSTEMATIC REVIEW;

ADENOCARCINOMA; BARRETT ESOPHAGUS; ESOPHAGEAL NEOPLASMS; HUMANS; INCIDENCE;

EID: 84861579225     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-300730     Document Type: Article

References (113)

1. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008;103:788-97.
2. Spechler SJ, Sharma P, Souza RF, et al. American Gastroenterological Association technical review on the management of Barrett's esophagus. Gastroenterology 2011;140:e18-52.
3. Shaheen NJ, Crosby MA, Bozymski EM, et al. Is there publication bias in the reporting of cancer risk in Barrett's esophagus? Gastroenterology 2000;119:333-8.
4. Nguyen DM, El-Serag HB, Henderson L, et al. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2009;7:1299-304.
5. Spechler SJ, Zeroogian JM, Antonioli DA, et al. Prevalence of metaplasia at the gastro-oesophageal junction. Lancet 1994;344:1533-6.
6. Spechler SJ. Barrett's esophagus: an overrated cancer risk factor. Gastroenterology 2000;119:587-9.
7. Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009;104:502-13.
8. Sikkema M, de Jonge PJ, Steyerberg EW, et al. Risk of esophageal adenocarcinoma and mortality in patients with Barrett's esophagus: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2010;8:235-44.
9. Yousef F, Cardwell C, Cantwell MM, et al. The incidence of esophageal cancer and high-grade dysplasia in Barrett's esophagus: a systematic review and metaanalysis. Am J Epidemiol 2008;168:237-49.
10. Wells GA, Shea B, O'connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality if nonrandomized studies in meta-analyses. http://www.ohri.ca/programs/clinical-epidemiology/oxford.htm (accessed Sep 2010).
11. Sedgwick P. Statistical question: meta-analyses III. BMJ 2011;342:d244.
12. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
13. Sutton AJ, Abrams KR, Jones DR, et al. Methods for meta-analysis in medical research. Chichester: Wiley, 2000.
14. Achkar E, Carey W. The cost of surveillance for adenocarcinoma complicating Barrett's esophagus. Am J Gastroenterol 1988;83:291-4.
15. Bartlesman JF, Hameeteman W, Tytgat GN. Barrett's oesophagus. Eur J Cancer Prev 1992;1:323-5.
16. Drewitz DJ, Sampliner RE, Garewal HS. The incidence of adenocarcinoma in Barrett's esophagus: a prospective study of 170 patients followed 4.8 years. Am J Gastroenterol 1997;92:212-15.
17. Ferraris R, Bonelli L, Conio M, et al. Incidence of Barrett's adenocarcinoma in an Italian population: an endoscopic surveillance programme. Gruppo Operativo per lo Studio delle Precancerosi Esofagee (GOSPE). Eur J Gastroenterol Hepatol 1997;9:881-5.
18. O'Connor JB, Falk GW, Richter JE. The incidence of adenocarcinoma and dysplasia in Barrett's esophagus: report on the Cleveland Clinic Barrett's Esophagus Registry. Am J Gastroenterol 1999;94:2037-42.
19. Ortiz A, Martinez de Haro LF, Parrilla P, et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996;83:274-8.
20. Reid BJ, Blount PL, Rubin CE, et al. Flow-cytometric and histological progression to malignancy in Barrett's esophagus: prospective endoscopic surveillance of a cohort. Gastroenterology 1992;102:1212-19.
21. Sharma P, Weston AP, Morales T, et al. Relative risk of dysplasia for patients with intestinal metaplasia in the distal oesophagus and in the gastric cardia. Gut 2000;46:9-13.
22. van der Burgh A, Dees J, Hop WC, et al. Oesophageal cancer is an uncommon cause of death in patients with Barrett's oesophagus. Gut 1996;39:5-8.
23. Weston AP, Krmpotich PT, Cherian R, et al. Prospective long-term endoscopic and histological follow-up of short segment Barrett's esophagus: comparison with traditional long segment Barrett's esophagus. Am J Gastroenterol 1997;92:407-13.
24. Cooper BT, Chapman W, Neumann CS, et al. Continuous treatment of Barrett's oesophagus patients with proton pump inhibitors up to 13 years: observations on regression and cancer incidence. Aliment Pharmacol Ther 2006;23:727-33.
25. Robertson CS, Mayberry JF, Nicholson DA, et al. Value of endoscopic surveillance in the detection of neoplastic change in Barrett's oesophagus. Br J Surg 1988;75:760-3.
26. Williamson WA, Ellis FH, Gibb SP, et al. Effect of antireflux operation on Barrett's mucosa. Ann Thorac Surg 1990;49:537-41.
27. Schoenfeld P, Johnston M, Piorkowski M, et al. Effectiveness and patient satisfaction with nurse-directed treatment of Barrett's esophagus. Am J Gastroenterol 1998;93:906-10.
28. Cook MB, Wild CP, Everett SM, et al. Risk of mortality and cancer incidence in Barrett's esophagus. Cancer Epidemiol Biomarkers Prev 2007;16:2090-6.
29. Lundell L, Miettinen P, Myrvold HE, et al. Long-term management of gastrooesophageal reflux disease with omeprazole or open antireflux surgery: results of a prospective, randomized clinical trial. The Nordic GORD Study Group. Eur J Gastroenterol Hepatol 2000;12:879-87.
30. Conio M, Cameron AJ, Romero Y, et al. Secular trends in the epidemiology and outcome of Barrett's oesophagus in Olmsted County, Minnesota. Gut 2001;48:304-9.
31. Sharma P, Falk GW, Weston AP, et al. Dysplasia and cancer in a large multicenter cohort of patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2006;4:566-72.
32. Alcedo J, Ferrandez A, Arenas J, et al. Trends in Barrett's esophagus diagnosis in Southern Europe: implications for surveillance. Dis Esophagus 2009;22:239-48.
33. Aldulaimi DM, Cox M, Nwokolo CU, et al. Barrett's surveillance is worthwhile and detects curable cancers. A prospective cohort study addressing cancer incidence, treatment outcome and survival. Eur J Gastroenterol Hepatol 2005;17:943-50.
34. Solaymani-Dodoran M, Logan RF, West J, et al. Risk of oesophageal cancer in Barrett's esophagus and gastroesophageal reflux. Gut 2004;53:1070-4.
35. Attwood SE, Barlow AP, Norris TL, et al. Barrett's oesophagus: effect of antireflux surgery on symptom control and development of complications. Br J Surg 1992;79:1050-3.
36. Bani-Hani K, Sue-Ling H, Johnston D, et al. Barrett's oesophagus: results from a 13-year surveillance programme. Eur J Gastroenterol Hepatol 2000;12:649-54.
37. Bright T, Schloithe A, Bull JA, et al. Outcome of endoscopy surveillance for Barrett's oesophagus. ANZ J Surg 2009;79:812-16.
38. Cameron AJ, Ott BJ, Payne WS. The incidence of adenocarcinoma in columnarlined (Barrett's) esophagus. N Engl J Med 1985;313:857-9.
39. Fitzgerald RC, Saeed IT, Khoo D, et al. Rigorous surveillance protocol increases detection of curable cancers associated with Barrett's esophagus. Dig Dis Sci 2001;46:1892-8.
40. Iftikhar SY, James PD, Steele RJ, et al. Length of Barrett's oesophagus: an important factor in the development of dysplasia and adenocarcinoma. Gut 1992;33:1155-8.
41. McDonald ML, Trastek VF, Allen MS, et al. Barretts's esophagus: does an antireflux procedure reduce the need for endoscopic surveillance? J Thorac Cardiovasc Surg 1996;111:1135-8; discussion 1139-40.
42. Moghissi K, Sharpe DA, Pender D. Adenocarcinoma and Barrett's oesophagus. A clinico-pathological study. Eur J Cardiothorac Surg 1993;7:126-31.
43. Olithselvan A, Gorard DA, McIntyre AS. A surveillance programme for Barrett's oesophagus in a UK general hospital. Eur J Gastroenterol Hepatol 2007;19:305-9.
44. Ovaska J, Miettinen M, Kivilaakso E. Adenocarcinoma arising in Barrett's esophagus. Dig Dis Sci 1989;34:1336-9.
45. Rana PS, Johnston DA. Incidence of adenocarcinoma and mortality in patients with Barrett's oesophagus diagnosed between 1976 and 1986: implications for endoscopic surveillance. Dis Esophagus 2000;13:28-31.
46. Savary M, Ollyo JB, Monnier P. Frequency and importance of endobrachyesophagus in reflux disease. In: Siewert JR, Holscher AH, eds. Diseases of the esophagus. Berlin: Springer-Verlag, 1984.
47. Spechler SJ, Lee E, Ahnen D, et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285:2331-8.
48. Streitz JM Jr, Ellis FH Jr, Tilden RL, et al. Endoscopic surveillance of Barrett's esophagus: a cost-effectiveness comparison with mammographic surveillance for breast cancer. Am J Gastroenterol 1998;93:911-15.
49. Watson RG, Porter KG, Sloan J. Incidence of adenocarcinoma in Barrett's esophagus and an evaluation of endoscopic surveillance. Eur J Gastroenterol Hepatol 1991;3:159-62.
50. Skinner DB. The incidence of cancer in Barrett's esophagus varies according to the series. In: Giuli R, McCallum RW, eds. Benign lesions of the esophagus and cancer. New York: Springer-Verlag, 1989.
51. Moayyedi P, Burch N, Akhtar-Danesh N, et al. Mortality rates in patients with Barrett's oesophagus. Aliment Pharmacol Ther 2008;27:316-20.
52. Wright TA, Gray MR, Morris AI, et al. Cost effectiveness of detecting Barrett's cancer. Gut 1996;39:574-9.
53. Roberts KJ, Harper E, Alderson D, et al. Long term survival and cost analysis of an annual Barrett's surveillance program. Eur J Gastroenterol Hepatol 2010;22:399-403.
54. Abela J, Going J, Mackenzie JF, et al. Systematic four quadrant biopsy detects Barrett's dysplasia in more patients than non-systematic biopsy. Am J Gastroenterol 2008;103:850-5.
55. Komorowski RA, Hogan WJ, Chausow DD. Barrett's ulcer: the clinical significance today. Am J Gastroenterol 1996;91:2310-13.
56. Abbas AE, Deschamps C, Cassivi SD, et al. Barrett's esophagus: the role of laparoscopic fundoplication. Ann Thorac Surg 2004;77:393-6.
57. Basu KK, Pick B, de Caestecker JS. Audit of a Barrett's epithelium surveillance database. Eur J Gastroenterol Hepatol 2004;16:171-5.
58. Biertho L, Dallemagne B, Dewandre JM, et al. Laparoscopic treatment of Barrett's esophagus: long-term results. Surg Endosc 2007;21:11-15.
59. Bowers SP, Mattar SG, Smith CD, et al. Clinical and histologic follow-up after antireflux surgery for Barrett's esophagus. J Gastrointest Surg 2002;6:532-8; discussion 539.
60. Chen LQ, Hu CY, Gaboury L, et al. Proliferative activity in Barrett's esophagus before and after antireflux surgery. Ann Surg 2001;234:172-80.
61. Conio M, Blanchi S, Lapertosa G, et al. Long-term endoscopic surveillance of patients with Barrett's esophagus. Incidence of dysplasia and adenocarcinoma: a prospective study. Am J Gastroenterol 2003;98:1931-9.
62. Csendes A, Braghetto I, Burdiles P, et al. Late results of the surgical treatment of 125 patients with short-segment Barrett esophagus. Arch Surg 2009;144:921-7.
63. DeMeester TR, Attwood SE, Smyrk TC, et al. Surgical therapy in Barrett's esophagus. Ann Surg 1990;212:528-40; discussion 540-2.
64. Desai KM, Soper NJ, Frisella MM, et al. Efficacy of laparoscopic antireflux surgery in patients with Barrett's esophagus. Am J Surg 2003;186:652-9.
65. Dulai GS, Shekelle PG, Jensen DM, et al. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort. Am J Gastroenterol 2005;100:775-83.
66. Eckardt VF, Kanzler G, Bernhard G. Life expectancy and cancer risk in patients with Barrett's esophagus: a prospective controlled investigation. Am J Med 2001;111:33-7.
67. Gatenby PA, Ramus JR, Caygill CP, et al. Treatment modality and risk of development of dysplasia and adenocarcinoma in columnar-lined esophagus. Dis Esophagus 2009;22:133-42.
68. Gladman L, Chapman W, Iqbal TH, et al. Barrett's oesophagus: an audit of surveillance over a 17-year period. Eur J Gastroenterol Hepatol 2006;18:271-6.
69. Gurski RR, Peters JH, Hagen JA, et al. Barrett's esophagus can and does regress after antireflux surgery: a study of prevalence and predictive features. J Am Coll Surg 2003;196:706-12; discussion 712-13.
70. Hage M, Siersema PD, van Dekken H, et al. Oesophageal cancer incidence and mortality in patients with long-segment Barrett's oesophagus after a mean followup of 12.7 years. Scand J Gastroenterol 2004;39:1175-9.
71. Hameeteman W, Tytgat GN, Houthoff HJ, et al. Barrett's esophagus: development of dysplasia and adenocarcinoma. Gastroenterology 1989;96:1249-56.
72. Hillman LC, Chiragakis L, Shadbolt B, et al. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus. Aliment Pharmacol Ther 2008;27:321-6.
73. Katz D, Rothstein R, Schned A, et al. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus. Am J Gastroenterol 1998;93:536-41.
74. Kelty CJ, Gough MD, Van Wyk Q, et al. Barrett's oesophagus: intestinal metaplasia is not essential for cancer risk. Scand J Gastroenterol 2007;42:1271-4.
75. Klinkenberg-Knol EC, Nelis F, Dent J, et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. Gastroenterology 2000;118:661-9.
76. Lim CH, Treanor D, Dixon MF, et al. Low-grade dysplasia in Barrett's esophagus has a high risk of progression. Endoscopy 2007;39:581-7.
77. Luostarinen ME, Mattila JJ, Auvinen OL, et al. Histological improvement of oesophagitis after Nissen fundoplication. Ann Med 1998;30:547-52.
78. Malesci A, Savarino V, Zentilin P, et al. Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996;44:700-5.
79. Martinek J, Benes M, Brandtl P, et al. Low incidence of adenocarcinoma and highgrade intraepithelial neoplasia in patients with Barrett's esophagus: a prospective cohort study. Endoscopy 2008;40:711-16.
80. Meining A, Ott R, Becker I, et al. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology onlydwhat is the clinical significance? Gut 2004;53:1402-7.
81. Miros M, Kerlin P, Walker N. Only patients with dysplasia progress to adenocarcinoma in Barrett's oesophagus. Gut 1991;32:1441-6.
82. Murphy SJ, Dickey W, Hughes D, et al. Surveillance for Barrett's oesophagus: results from a programme in Northern Ireland. Eur J Gastroenterol Hepatol 2005;17:1029-35.
83. Murray L, Watson P, Johnston B, et al. Risk of adenocarcinoma in Barrett's oesophagus: population based study. BMJ 2003;327:534-5.
84. Oberg S, Wenner J, Johansson J, et al. Barrett esophagus: risk factors for progression to dysplasia and adenocarcinoma. Ann Surg 2005;242:49-54.
85. Oelschlager BK, Barreca M, Chang L, et al. Clinical and pathologic response of Barrett's esophagus to laparoscopic antireflux surgery. Ann Surg 2003;238:458-64; discussion 464-6.
86. O'Riordan JM, Byrne PJ, Ravi N, et al. Long-term clinical and pathologic response of Barrett's esophagus after antireflux surgery. Am J Surg 2004;188:27-33.
87. Parrilla P, Martinez de Haro LF, Ortiz A, et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett's esophagus. Ann Surg 2003;237:291-8.
88. Patti MG, Arcerito M, Feo CV, et al. Barrett's esophagus: a surgical disease. J Gastrointest Surg 1999;3:397-403; discussion 403-4.
89. Peters FT, Ganesh S, Kuipers EJ, et al. Endoscopic regression of Barrett's oesophagus during omeprazole treatment; a randomised double blind study. Gut 1999;45:489-94.
90. Reid BJ, Levine DS, Longton G, et al. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- and highrisk patient subsets. Am J Gastroenterol 2000;95:1669-76.
91. Sagar PM, Ackroyd R, Hosie KB, et al. Regression and progression of Barrett's oesophagus after antireflux surgery. Br J Surg 1995;82:806-10.
92. Spechler SJ, Robbins AH, Rubins HB, et al. Adenocarcinoma and Barrett's esophagus. An overrated risk? Gastroenterology 1984;87:927-33.
93. Switzer-Taylor V, Schlup M, Lubcke R, et al. Barrett's esophagus: a retrospective analysis of 13 years surveillance. J Gastroenterol Hepatol 2008;23:1362-7.
94. Teodori L, Gohde W, Persiani M, et al. DNA/protein flow cytometry as a predictive marker of malignancy in dysplasia-free Barrett's esophagus: thirteen-year follow-up study on a cohort of patients. Cytometry 1998;34:257-63.
95. Vieth M, Schubert B, Lang-Schwarz K, et al. Frequency of Barrett's neoplasia after initial negative endoscopy with biopsy: a long-term histopathological follow-up study. Endoscopy 2006;38:1201-5.
96. von Rahden BH, Stein HJ, Weber A, et al. Critical reappraisal of current surveillance strategies for Barrett's esophagus: analysis of a large German Barrett's database. Dis Esophagus 2008;21:685-9.
97. Wilkinson SP, Biddlestone L, Gore S, et al. Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999;13:1205-9.
98. Younes M, Ertan A, Lechago LV, et al. p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia. Dig Dis Sci 1997;42:697-701.
99. Zaninotto G, Cassaro M, Pennelli G, et al. Barrett's epithelium after antireflux surgery. J Gastrointest Surg 2005;9:1253-60; discussion 1260-1.
100. Musana AK, Resnick JM, Torbey CF, et al. Barrett's esophagus: incidence and prevalence estimates in a rural Mid-Western population. Am J Gastroenterol 2008;103:516-24.
101. Hurschler D, Borovicka J, Neuweiler J, et al. Increased detection rates of Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma. Swiss Med Wkly 2003;133:507-14.
102. Low DE, Levine DS, Dail DH, et al. Histological and anatomic changes in Barrett's esophagus after antireflux surgery. Am J Gastroenterol 1999;94:80-5.
103. Lundell L, Miettinen P, Myrvold HE, et al. Comparison of outcomes twelve years after antireflux surgery or omeprazole maintenance therapy for reflux esophagitis. Clin Gastroenterol Hepatol 2009;7:1292-8; quiz 1260.
104. Csendes A, Burdiles P, Braghetto I, et al. Adenocarcinoma appearing very late after antireflux surgery for Barrett's esophagus: long-term follow-up, review of the literature, and addition of six patients. J Gastrointest Surg 2004;8:434-41.
105. Srinivasan R, Katz PO, Ramakrishnan A, et al. Maximal acid reflux control for Barrett's oesophagus: feasible and effective. Aliment Pharmacol Ther 2001;15:519-24.
106. Williamson WA, Ellis FH Jr, Gibb SP, et al. Barrett's esophagus. Prevalence and incidence of adenocarcinoma. Arch Intern Med 1991;151:2212-16.
107. Ajumobi A, Bahjri K, Jackson C, et al. Surveillance in Barrett's esophagus: an audit of practice. Dig Dis Sci 2010;55:1615-21.
108. Wong T, Tian J, Nagar A. Barrett's surveillance identifies patients with early esophageal adenocarcinoma. Am J Med 2010;123:462-7.
109. Wani S, Falk G, Hall M, et al. Patients with non-dysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2011;9:220-7.
110. Jung KW, Talley NJ, Romero Y, et al. Epidemiology and natural history of intestinal metaplasia of the gastroesophageal junction and Barrett's esophagus: a populationbased study. Am J Gastroenterol 2011;106:1447-55; quiz 1456.
111. Schouten LJ, Steevens J, Huysentruyt CJ, et al. Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus. Clin Gastroenterol Hepatol 2011;9:754-61.
112. Rudolph RE, Vaughan TL, Storer BE, et al. Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med 2000;132:612-20.
113. Bhat S, Coleman HG, Yousef F, et al. Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study. J Natl Cancer Inst 2011;103:1049-57.